Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Resverlogix Corp. T.RVX

Alternate Symbol(s):  RVXCF | T.RVX.W.A

Resverlogix Corp clinical-stage biotechnology company. The company is developing an advanced epigenetic drug called apabetalone for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, orphan diseases, and neurodegenerative diseases.


Recent & Breaking News (TSX:RVX)

Resverlogix Plans COVID-19 Clinical Trial Program Launch

GlobeNewswire June 1, 2020

Resverlogix Announces Participation at the American College of Cardiology Scientific Sessions together with the World Congress of Cardiology Virtual

GlobeNewswire March 31, 2020

Resverlogix Announces Publication of Key Apabetalone Study BETonMACE in the Journal of the American Medical Association

GlobeNewswire March 30, 2020

Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication

GlobeNewswire March 24, 2020

The Top Healthcare Bullboards: Jan - Mar 2020

Stockhouse Editorial March 23, 2020

Resverlogix Invites Collaborations for use of Apabetalone in Trials and Studies to Combat the Spread of COVID-19 Based on New Research

GlobeNewswire March 23, 2020

Resverlogix Receives US FDA Breakthrough Therapy Designation for Apabetalone

GlobeNewswire February 3, 2020

CORRECTION: Resverlogix Confirms a Significant Corporate Advancement Establishing Apabetalone as a Potential Blockbuster Combination Drug in High-risk Diabetes Patients with CVD

GlobeNewswire January 13, 2020

Resverlogix Confirms a Significant Corporate Advancement Establishing Apabetalone as a Potential Blockbuster Combination Drug in High-risk Diabetes Patients with CVD

GlobeNewswire January 13, 2020

Resverlogix Appoints Dicky To to its Board of Directors

GlobeNewswire December 20, 2019

Zenith Epigenetics Announces Clinical Advancement of ZEN-3694

GlobeNewswire December 19, 2019

Resverlogix Announces Change to its Board of Directors

GlobeNewswire December 11, 2019

Reminder: Resverlogix to Hold Conference Call and Webcast on December 6th, 2019

GlobeNewswire December 5, 2019

Resverlogix to Present at the Clinical Trials on Alzheimer's Disease Congress 2019

GlobeNewswire December 2, 2019

Resverlogix Announces Warrant Exercise Incentive Program

GlobeNewswire November 25, 2019

Resverlogix to Hold BETonMACE Conference Call and Webcast on November 18, 2019

GlobeNewswire November 12, 2019

Resverlogix Announces Voting Results from the 2019 Annual Meeting of Shareholders

GlobeNewswire October 31, 2019

Zenith Announces Voting Results from the 2019 Annual and Special Meeting of Shareholders

GlobeNewswire October 31, 2019

Resverlogix Announces Topline Results in BETonMACE Phase 3 Epigenetics Trial

GlobeNewswire September 30, 2019

Resverlogix Announces US$12 Million Debenture Financing and Full Repayment of Loan

GlobeNewswire September 27, 2019